MDA5-related juvenile dermatomyositis and interstitial lung disease: Transitioning from rapid progression to a quiescent state in three pediatric cases from South Africa, along with a literature review. - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

MDA5-related juvenile dermatomyositis and interstitial lung disease: Transitioning from rapid progression to a quiescent state in three pediatric cases from South Africa, along with a literature review.

  • By

  • Maurane Lepage

  • Gabriella Pereira

  • Shehnaaz Akhalwaya

  • Taryn Gray

  • Marco Zampoli

  • Mignon McCulloch

  • Peter Nourse

  • Ashton Coetzee

  • Claire Procter

  • Khanyisile Hlongwa

  • Tanyia Pillay

  • Kate Webb

  • April 22, 2026

Share

Objective:

To document the clinical features and disease course of three African children with anti-MDA5-associated juvenile dermatomyositis (JDM) and interstitial lung disease (ILD), focusing on specific clinical outcomes and treatment responses, and to review the literature on rapidly progressive ILD related to MDA5.

Approach:
    Key Findings:
    • Anti-MDA5 autoantibodies are associated with a unique clinical profile in JDM, including higher risks for ILD and RP-ILD, as evidenced in the presented cases.
    • The prevalence of anti-MDA5 in JDM varies significantly by geographic and ethnic backgrounds, with the cases highlighting this variability.
    • The first documented cases of anti-MDA5-associated JDM in African children were presented, showcasing distinct clinical features and treatment challenges.
    Interpretation:

    The cases illustrate the complexity of managing anti-MDA5-associated JDM and ILD, emphasizing the need for tailored therapeutic strategies in diverse populations, particularly in underrepresented groups.

    Limitations:
    • Limited number of cases presented restricts generalizability and may introduce selection bias.
    • Lack of comprehensive data on anti-MDA5-associated JDM in African populations limits the understanding of the disease in this context.
    Conclusion:

    The study underscores the importance of recognizing and treating anti-MDA5-associated JDM and ILD in children, particularly in underrepresented populations, and suggests the need for further research to optimize management strategies in light of existing literature.

Original Source(s)

Related Content